All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0109141" target="_blank" >RIV/00843989:_____/21:E0109141 - isvavai.cz</a>

  • Alternative codes found

    RIV/65269705:_____/21:00075847 RIV/00064165:_____/21:10429479

  • Result on the web

    <a href="https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1002/ajh.26282</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1002/ajh.26282" target="_blank" >10.1002/ajh.26282</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

  • Original language description

    The assessment of patient-reported outcomes (PROs) has become an important component in clinical trials as they provide information on the impact of a disease and treatment from the patient's perspective. The BOSTON trial is the first study of a bortezomib-based triplet therapy that showed lower rates of overall and Grade ? 2 PN compared with doublet Vd while conferring a longer PFS and fewer clinic visits than standard twice weekly Vd. As the survival of patients with MM are improving, the need to minimize cumulative side effects such as PN becomes more important to improve QoL. The reduction in PN-related pain and sensory symptoms observed with XVd in this setting of increased PFS, time to next therapy, and patient-preferred oral administration supports a potentially improved patient experience and decreased health care burden and long-term morbidity.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30205 - Hematology

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    American journal of hematology

  • ISSN

    0361-8609

  • e-ISSN

    1096-8652

  • Volume of the periodical

    96

  • Issue of the periodical within the volume

    10

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    1

  • Pages from-to

    e383-e386

  • UT code for WoS article

    000671882800001

  • EID of the result in the Scopus database

    2-s2.0-85109791260